Q32 Bio Inc. (QTTB) reported Q4 2025 earnings of $4.58 per share. No consensus estimate was available for comparison. Total revenue was $53.7 million.
Q32 Bio Inc. is a clinical-stage biotechnology company that develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases. The company’s lead candidate, Bempikibart (ADX-914), is a fully human anti-interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function.
The company is focused on treating conditions, including atopic dermatitis and alopecia areata by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.